Gut bug may predict prostate cancer drug response

NCT ID NCT06242509

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated Jun 13, 2026 · Updated 3 times

Summary

This study explores whether a specific gut bacterium, Akkermansia muciniphila, can serve as a marker to predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will measure the levels of this bacterium in stool samples before and after treatment in 52 men with metastatic castration-resistant prostate cancer. The goal is to see if an increase in this bacterium is linked to a better treatment response, potentially leading to a simple, non-invasive test to guide therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hôpital Saint Louis AP-HP
RECRUITING

Paris, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER